Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,471
  • Shares Outstanding, K 37,780
  • Annual Sales, $ 140,140 K
  • Annual Income, $ 67,040 K
  • 60-Month Beta 1.51
  • Price/Sales 0.56
  • Price/Cash Flow 1.10
  • Price/Book 1.07
Trade SCYX with:

Options Overview Details

View History
  • Implied Volatility 77.47% ( -30.17%)
  • Historical Volatility 60.47%
  • IV Percentile 8%
  • IV Rank 7.23%
  • IV High 923.84% on 06/24/24
  • IV Low 11.47% on 07/15/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 30
  • Volume Avg (30-Day) 56
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,772
  • Open Int (30-Day) 1,651

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year 2.46
  • Growth Rate Est. (year over year) -107.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.75 +21.71%
on 06/21/24
2.29 -6.99%
on 07/16/24
+0.24 (+12.70%)
since 06/18/24
3-Month
1.42 +50.00%
on 04/25/24
3.07 -30.62%
on 05/20/24
+0.69 (+47.92%)
since 04/19/24
52-Week
1.35 +57.78%
on 03/19/24
3.87 -44.96%
on 09/05/23
-0.68 (-24.20%)
since 07/19/23

Most Recent Stories

More News
Scynexis: Q1 Earnings Snapshot

Scynexis: Q1 Earnings Snapshot

SCYX : 2.13 (+1.91%)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 2.13 (+1.91%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...

SCYX : 2.13 (+1.91%)
The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of Investors

/PRNewswire/ -- The Law Offices of Frank R. Cruz announces an investigation of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX) on behalf of...

SCYX : 2.13 (+1.91%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...

SCYX : 2.13 (+1.91%)
Scynexis: Q2 Earnings Snapshot

Scynexis: Q2 Earnings Snapshot

SCYX : 2.13 (+1.91%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating SCYNEXIS, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

SCYX : 2.13 (+1.91%)
Scynexis: Q1 Earnings Snapshot

Scynexis: Q1 Earnings Snapshot

SCYX : 2.13 (+1.91%)
SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections

SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions

SCYX : 2.13 (+1.91%)
GSK : 39.35 (-0.03%)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 2.13 (+1.91%)

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

3rd Resistance Point 2.34
2nd Resistance Point 2.24
1st Resistance Point 2.19
Last Price 2.13
1st Support Level 2.04
2nd Support Level 1.94
3rd Support Level 1.89

See More

52-Week High 3.87
Fibonacci 61.8% 2.91
Fibonacci 50% 2.61
Fibonacci 38.2% 2.31
Last Price 2.13
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar